Companies › Quanta Therapeutics
3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| QTX3544 KRAS G12V inhibitor | KRAS | Phase 1 | Advanced Solid Tumors | Jan 2027 |
| QTX3034 KRAS G12D inhibitor | KRAS | Phase 1 | Solid Tumors | Apr 2027 |
| QTX3046 KRAS G12D inhibitor | KRAS | Phase 1 | Advanced Solid Tumor | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06715124 | QTX3544 | Phase 1 | Advanced Solid Tumors | Oncology | Jan 2027 |
| NCT06227377 | QTX3034 | Phase 1 | Solid Tumors | Oncology | Apr 2027 |
| NCT06428500 | QTX3046 | Phase 1 | Advanced Solid Tumor | Oncology | Jul 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.